| Mrs Shannon Planck, | |
|
378 Prospect St, Barre, VT 05641-5421 | |
| (802) 476-4166 | |
| Not Available |
| Full Name | Mrs Shannon Planck |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 378 Prospect St, Barre, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184089211 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 144.0115343 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Shannon Planck, 118 Delmont Ave, Barre, VT 05641-3215 Ph: (802) 734-0805 | Mrs Shannon Planck, 378 Prospect St, Barre, VT 05641-5421 Ph: (802) 476-4166 |
News Archive
Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.
The first ever analysis of the global and regional prevalence of dependence upon the four major categories of illicit drugs – amphetamine, cannabis, cocaine, and opioids (such as heroin) – has revealed that opioid dependence causes the greatest health burden (overall death and illness) of all the illicit drugs. The results come from new analysis of the Global Burden of Disease Study 2010, and are published in The Lancet.
BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision's proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.
Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced its sponsorship of the first annual Big Walk on Wilson's (BIG WOW). The event will take place on September 19, 2015 in sixteen cities across North America to increase awareness of Wilson's Disease and raise funds for the Wilson Disease Association.
› Verified 6 days ago
Mrs. Judith Carol Yandow, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20 Clifton Street, Barre, VT 05641 Phone: 802-479-7039 | |
Patricia S Taffel, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 64 West Rd, Barre, VT 05641 Phone: 802-479-2109 | |
Miss Kristy Lyn Antonacci, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 98 Hospitality Dr, Barre, VT 05641 Phone: 802-229-0308 |